Literature DB >> 9140466

Upper respiratory tract surface areas and volumes of laboratory animals and humans: considerations for dosimetry models.

M G Ménache1, L M Hanna, E A Gross, S R Lou, S J Zinreich, D A Leopold, A M Jarabek, F J Miller.   

Abstract

To facilitate the development of regional respiratory tract dosimetry comparisons between laboratory animal species and humans, published surface area (SA) and volume (VOL) data for the upper respiratory tract (URT) were reviewed. The review of the literature revealed that (1) different studies used different techniques to prepare specimens and make measurements, (2) different areas of the URT were measured, and (3) URT surface areas and volumes have been reported for a limited number of individual subjects within a species but for a relatively wide range of species. The published data are summarized in tables in this article. New measurements made in an F344 rat and in a female human subject are also presented. Despite the differences in experimental protocols, it was possible to fit allometric scaling equations to the data: In(SA, cm2) = -0.34 + 0.52 In(body weight, g) and In(VOL, cm3) = 1.70 + 0.78 In(body weight, g). Separate scaling equations were also fitted for rats alone. To illustrate the use of these scaling equations in quantitative human health risk assessment, two dose metrics (fractional absorption/cm2 URT SA and fractional absorption/g body weight) for predicted URT uptake in laboratory animals and humans were calculated for acrolein and epichlorohydrin. Expressed as an animal-to-human ratio, the 95% confidence interval for URT SA could change the predicted dose ratio by up to a factor of 2. Additional studies are needed to describe the entire URT (from the nares through the larynx) quantitatively and to decrease variability in scaling equation predictions as well as to develop additional species-specific scaling equations. Three-dimensional imaging techniques provide a noninvasive method to obtain URT surface areas and volumes in humans and the larger laboratory animals. Comparisons of magnetic resonance image (MRI) and computed tomography (CT) scans made as part of this study suggest that the greater clarity of the mucosal-air interface in the CT image provides better resolution for the study of anatomic features. Because there is no radiation exposure associated with MRI imaging, however, it is more safely used than CT scans in making repeated measurements in a subject to elucidate changes in URT geometry associated with normal nasal cycling or other physiological changes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140466     DOI: 10.1080/00984109708984003

Source DB:  PubMed          Journal:  J Toxicol Environ Health        ISSN: 0098-4108


  15 in total

1.  A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression.

Authors:  Mohamed A Kamal; Ronald Gieschke; Annabelle Lemenuel-Diot; Catherine A A Beauchemin; Patrick F Smith; Craig R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

2.  Combination antiviral therapy for influenza: predictions from modeling of human infections.

Authors:  Alan S Perelson; Libin Rong; Frederick G Hayden
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

3.  Nasal aerodynamics protects brain and lung from inhaled dust in subterranean diggers, Ellobius talpinus.

Authors:  M P Moshkin; D V Petrovski; A E Akulov; A V Romashchenko; L A Gerlinskaya; V L Ganimedov; M I Muchnaya; A S Sadovsky; I V Koptyug; A A Savelov; S Yu Troitsky; Y M Moshkn; V I Bukhtiyarov; N A Kolchanov; R Z Sagdeev; V M Fomin
Journal:  Proc Biol Sci       Date:  2014-10-07       Impact factor: 5.349

4.  Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular.

Authors:  Armaghan Emami; Jeff Tepper; Brian Short; Tony L Yaksh; Alison M Bendele; Thulasi Ramani; Alvaro F Cisternas; Jay H Chang; R Daniel Mellon
Journal:  Int J Toxicol       Date:  2017-12-21       Impact factor: 2.032

5.  Kinetics of influenza A virus infection in humans.

Authors:  Prasith Baccam; Catherine Beauchemin; Catherine A Macken; Frederick G Hayden; Alan S Perelson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans.

Authors:  Prabhas Jagdale; Armin Sepp; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-10-20       Impact factor: 2.410

7.  Contributions of mouse genetic background and age on anterior lens capsule thickness.

Authors:  Brian P Danysh; Kirk J Czymmek; Pecos T Olurin; Jacob G Sivak; Melinda K Duncan
Journal:  Anat Rec (Hoboken)       Date:  2008-12       Impact factor: 2.064

8.  The institutional review board is an impediment to human research: the result is more animal-based research.

Authors:  Mark J Rice
Journal:  Philos Ethics Humanit Med       Date:  2011-06-07       Impact factor: 2.464

9.  Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization.

Authors:  Stefan Sturm; Annabelle Lemenuel-Diot; Kashyap Patel; Leonid Gibiansky; Rajinder Bhardwaj; Patrick F Smith; Steve Dang; Elke Zwanziger; Clare Nasmyth-Miller; Patanjali Ravva
Journal:  Br J Clin Pharmacol       Date:  2020-09-09       Impact factor: 4.335

10.  Reducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load.

Authors:  Stephen M Petrie; Teagan Guarnaccia; Karen L Laurie; Aeron C Hurt; Jodie McVernon; James M McCaw
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.